Prof. Dr. Anna LICATA, MD
Dr. Marina VILLANUEVA PAZ
Prof. Dr. Jane Grove
YOUNG INVESTIGATORS AFTERWORKS SERIES‘ COORDINATOR
Prof. Ann DALY
Monthly International Seminar Series on Liver Toxicity and Steatotic Liver Disease and different EASL studio topics for DHILI will be organised at a later stage.
As a proposal within our educational activities, we will be launching from January a series of talks on Liver Toxicity and Steatotic Liver Disease, ONCE monthly, given by international experts in the field. The session outline would be a talk of around 45 min with 15 min left for discussion. Conferences will be held on the 3rd Wednesday of each month at 16.30h (CET) starting from January 17th 2024.
These international seminar series are the result of an outstanding collaboration between the EASL DHILI Consortium (https://easldhiliconsortium.eu/) and the Halt-RONIN (UKRI-Horizon Europe) https://halt-ronin.com/
The objectives are:
- to improve collaboration between different group experts encompassing clinical investigators, researchers, basic scientists, industry partners and regulators.
- To foster scientific progress by disseminating the latest breakthroughs in research on hepatotoxicity and metabolic dysfunction-associated steatotic liver disease
This presentation unfolds at the intersection of pioneering research and innovative solutions in hepatic diseases. «Translational Basic Research: Navigating Opportunities and Challenges in the Development of Therapeutic RNA Molecules for Addressing Hepatic Diseases via Magnesium Homeostasis» explores a transformative approach to hepatic conditions by leveraging the nuanced dynamics of magnesium homeostasis.
The session aims to navigate through the promising opportunities that therapeutic RNA molecules present in reshaping the landscape of hepatic diseases. By delving into the profound impact of magnesium homeostasis, attendees will gain insights into the pivotal role it plays in the development and application of therapeutic interventions. Together, we aspire to pave the way for groundbreaking advancements in hepatic healthcare.